Get the Stockscreener App
17.55
3.24%
0.55
After Hours:
17.70
0.15
+0.85%
Summit Therapeutics Inc stock is traded at $17.55, with a volume of 4.27M.
It is up +3.24% in the last 24 hours and up +16.11% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$17.00
Open:
$17.2
24h Volume:
4.27M
Relative Volume:
0.81
Market Cap:
$14.00B
Revenue:
$220.00K
Net Income/Loss:
$-1.21B
P/E Ratio:
-10.94
EPS:
-1.6039
Net Cash Flow:
$-387.48M
1W Performance:
-0.31%
1M Performance:
+16.11%
6M Performance:
+9.14%
1Y Performance:
-5.65%
1-Day Range:
$17.14
$17.70
1-Week Range:
$16.80
$18.32
52-Week Range:
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.55 | 14.00B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Why Is SMMT Stock Tumbling Today? - Stocktwits
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - benzinga.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga
Why is Summit Therapeutics stock surging today? - Investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Nigeria
Ivonescimab shows statistically significant OS vs pembrolizumab in HARMONi-2, Summit Therapeutics notes - TradingView
Summit Therapeutics stock rises on positive survival data - Investing.com
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet - Seeking Alpha
Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res - GuruFocus
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Yahoo Finance
Cantor Fitzgerald reiterates Summit Therapeutics stock rating - Investing.com
Weekly Recap: HARMONi Phase III PFS improvement and Bernstein upgrade - TradingView
Summit Therapeutics Inc. (SMMT) Stock Analysis: Assessing a Potential 107.71% Upside in Biotech - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? - Yahoo Finance
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab - Yahoo Finance
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Movi - Benzinga
Summit Therapeutics stock jumps on partner’s cancer trial data - Investing.com
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy - Sahm
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology - Business Wire
Summit Therapeutics Inc. (SMMT): Growth Potential and Analyst Consensus with 117.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT) Trading Up 7.2%Still a Buy? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright - MarketBeat
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year LowHere's Why - MarketBeat
Summit Therapeutics (SMMT) Shares Drop 8.5% Amid Valuation Conce - GuruFocus
Summit Therapeutics Inc. (SMMT) Stock Analysis: A 114% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT): What Could Drive Its Next Move? - Kalkine Media
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7%Here's Why - MarketBeat
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
SMMT - Finviz
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Singapore
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside - TradingView
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab - GuruFocus
Summit lead drug granted China label expansion (SMMT:NASDAQ) - Seeking Alpha
Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum? - Kalkine Media
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC - marketscreener.com
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):